Can Junshi Biosciences Surpass Pfizer in the Era of ADCs with Immune Checkpoint Inhibitors?
Click the blue text Follow us This issue Highlights of At the 2025 WCLC, Junshi Biosciences unveiled the groundbreaking phase I clinical data of its PD-L1 ADC (HLX43), attracting widespread attention in the industry. As the next frontier in the field of immune checkpoint inhibitors, PD-L1 ADC integrates the “dual strike” mechanism of immunotherapy and … Read more